Vertex Pharmaceuticals INC / Ma 10-Q quarterly reports

Vertex Pharmaceuticals Inc. announced robust financial results for the first quarter of 2026, driven by strong performance in its cystic fibrosis franchise and diversification into new disease areas.

Vertex Pharmaceuticals reported an 11% increase in net product revenues for the third quarter of 2025, driven by strong demand for TRIKAFTA/KAFTRIO and successful launches of ALYFTREK, CASGEVY, and JOURNAVX.

Vertex Pharmaceuticals reported a significant turnaround in Q2 2025, achieving $1.03 billion in net income driven by strong product revenue growth from TRIKAFTA/KAFTRIO and successful launches of ALYFTREK, CASGEVY, and JOURNAVX.

Vertex Pharmaceuticals reports a 3% increase in total revenue for Q1 2025, driven by TRIKAFTA/KAFTRIO and ALYFTREK, while announcing pipeline advancements and a leadership transition.

Vertex Pharmaceuticals' Q3 2024 results show revenue growth driven by cystic fibrosis treatments, but a net loss for the nine-month period due to a significant acquisition.

Vertex Pharmaceuticals reported a net loss for the second quarter of 2024, primarily due to a significant expense related to the acquisition of Alpine Immune Sciences, despite a revenue increase in their cystic fibrosis (CF) product line.

Vertex Pharmaceuticals reported a strong first quarter in 2024, with a 13% increase in net product revenues driven by its cystic fibrosis franchise and advancements in its pipeline.